| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.4 | 1e-36 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.27 | 1e-14 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.36 | 1e-14 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-13 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-11 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-10 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.19 | 4e-09 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-09 |